medac and Clinigen, a global specialty pharmaceutical services Group, are expanding their existing cooperation. Six key drugs produced by medac in the fields of oncology, haematology and immune-mediated diseases will be exclusively licensed and distributed by Clinigen in Australia, parts of Southeast Asia and China (APAC)

During a satellite symposium organised by medac at the annual congress of the European Alliance of Associations for Rheumatology (EULAR) 2025 in Barcelona, experts presented new real-world findings on methotrexate (MTX) in combination therapy for patients with rheumatoid arthritis (RA).

With the support of an independent educational grant from medac, Medscape has released an on-demand recording of the symposium “Optimizing Conditioning Regimens for HSCT in AML/MDS: Balancing Strategies for Improved Outcome,” presented at the EBMT 2025 Annual Meeting in Florence. The session featured expert insights into innovative conditioning strategies aimed at improving outcomes in hematopoietic stem cell transplantation (HSCT).

medac Group, a trusted partner in contract development and manufacturing, proudly announces the successful commissioning of its latest investment: the third production line at oncomed, a state-of-the-art production site in the Czech Republic operated by medac. This new production line is specifically designed for the high-quality manufacturing of prefilled syringes and cartridges, reinforcing medac's commitment to innovation, efficiency, and patient safety.

medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients aged 1 year and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).